Testing XH-S003 for people with PNH
Part of Blood & lymphatic clinical trials.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You weigh at least 40 kg (88 lbs) and have a BMI of 18 or above
- You have been diagnosed with PNH based on blood test results from the last 6 months
- You have not received complement inhibitor therapy before
- Your LDH level (a marker of red blood cell breakdown) is higher than normal on two separate tests during screening
- You have low hemoglobin (below 100 g/L) or have needed a blood transfusion due to PNH-related anemia during screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests an investigational drug called EA5 for people with PNH, a rare blood disease where red blood cells break down too quickly. It is for adults who either have never taken a complement inhibitor or stopped taking one recently, and who still have signs or symptoms of PNH.
This Phase 2 trial studies NM8074 in people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Soliris. It aims to improve PNH control by targeting the disease while you stay on your current Soliris treatment.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
Hear when a new PNH - Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.